Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
Negrier S, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C, Escudier B; Groupe Français d'Immunothérapie. Negrier S, et al. Among authors: chevreau c. World J Urol. 2005 Jul;23(3):161-5. doi: 10.1007/s00345-004-0467-z. Epub 2005 Feb 12. World J Urol. 2005. PMID: 15711829
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Negrier S, et al. Among authors: chevreau c. N Engl J Med. 1998 Apr 30;338(18):1272-8. doi: 10.1056/NEJM199804303381805. N Engl J Med. 1998. PMID: 9562581 Free article. Clinical Trial.
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard JY, Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M, Négrier S. Ravaud A, et al. Among authors: chevreau c. J Clin Oncol. 1998 Aug;16(8):2728-32. doi: 10.1200/JCO.1998.16.8.2728. J Clin Oncol. 1998. PMID: 9704724 Clinical Trial.
[Cancer of the kidney in the adult].
Delord JP, Alexandre J, Chevreau C, Escudier B. Delord JP, et al. Among authors: chevreau c. Bull Cancer. 1998 Sep;(1 Suppl):4-15. Bull Cancer. 1998. PMID: 9817068 Review. French.
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T, Négrier S, Chevreau C, Avril MF, Baume D, Cupissol D, Oskam R, de Peuter R, Vinke J, Herrera A, Escudier B. Dorval T, et al. Among authors: chevreau c. Cancer. 1999 Mar 1;85(5):1060-6. doi: 10.1002/(sici)1097-0142(19990301)85:5<1060::aid-cncr8>3.0.co;2-2. Cancer. 1999. PMID: 10091789 Clinical Trial.
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Négrier S. Escudier B, et al. Among authors: chevreau c. J Clin Oncol. 1999 Jul;17(7):2039-43. doi: 10.1200/JCO.1999.17.7.2039. J Clin Oncol. 1999. PMID: 10561255 Clinical Trial.
316 results